Maternal Health Market Outlook, 2030

The global maternal health market spanning prenatal diagnostics and screening, obstetric drugs and devices, facility-and home-based care, digital/femtech tools, and postpartum services is being reshaped by culture, urbanization, and rapid innovation. According to the World Health Organisation, maternal health services include "promoting, preventing, therapeutic, or rehabilitation facility or care for mother and child." Health problems are also becoming more widely known. However, the majority of developing countries are unable to achieve the anticipated reductions in child and maternal mortality because of insufficient access to healthcare services and a lack of awareness. For instance, the Indian government offers a variety of services in India, including as the Janani Suraksha Yojana, Janani Express, 1098 service, facility-based newborn care service, and home-based newborn care service. Key trend include the mainstreaming of tele-obstetrics and remote monitoring (BP cuffs, fetal dopplers, glucose sensors) bundled into app-based care models. In April 2022, A new prenatal test, called STORK (Short-read Transpore Rapid Karyotyping), was developed by researchers at Columbia University Fertility Center that can determine if a fetus or embryo has the right number of chromosomes at a fraction of the time and cost of currently available clinical genetic tests. The test can be used in the doctor’s office at the point of care, delivers results in less than two hours, and is about 10 times less expensive to process per sample than current tests. Urban growth also exposes inequities women in informal settlements often face overcrowded public facilities, out-of-pocket costs, and transport delays sustaining a parallel need for low-cost diagnostics, community outreach, and last-mile supply of essentials (e.g., iron-folate, magnesium sulfate, and oxytocin). Policy and regulation form a tight perimeter, essential obstetric medicines rely on stringent GMP and often WHO prequalification, devices require FDA/CE approvals and ISO 13485 quality systems, diagnostics may need CLIA or equivalent authorization and external quality assessment, digital tools handling reproductive health data must comply with GDPR/HIPAA-like privacy regimes and local data-residency rules.

According to the research report “Global Maternal Health Market Outlook, 2030”, the global Maternal Health market is projected to reach market size of USD 41.21 billion by 2030 increasing from USD 25.37 billion in 2024, growing with 8.61% CAGR by 2025-30. The increasing incidence of chronic conditions among women, such as cancer and osteoporosis, is the major growth driver of the market. These conditions often require gender-specific measures for prevention, diagnosis, and treatment. The risk factors associated with the occurrence of such diseases are family history, increasing age, early onset of periods or menopause and obesity, among others. For example, in March 2021, the World Health Organization (WHO) initiated the Global Breast Cancer Initiative (GBCI) intending to decrease breast cancer mortality rates by 2.5% annually until 2040, thereby potentially saving 2.5 million lives. Mallinckrodt Inc. is a global company that develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. The fourth-quarter 2024 net sales were $492.1 million, compared to $469.3 million in 2023. The net sales of the company in fiscal year 2024 were $1.98 billion, an increase of 6.1% from 2023. Technological drivers are especially visible with tele obstetrics, remote monitoring, AI based risk stratification, handheld ultrasound, and wearable maternal sensors unlocking new service models and creating opportunities for both femtech companies and traditional medtech firms. Conferences, summits and seminars are focal points for these developments. The FIGO World Congress, regional maternal and child health summits, femtech and women’s health innovation events, and specialized maternal mental health conferences bring together stakeholders to showcase products, present clinical evidence, and forge partnerships which makes such events both demand generators and deal making venues. In May 2022, Mirvie raised a total of USD 90 million following the closing of its series B funding. The funding encouraged Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.

Market Drivers

• Growing Awareness and Education: The increasing awareness about the importance of maternal care, fueled by government campaigns, healthcare NGOs, and digital health education platforms. Women are now more informed about prenatal and postnatal care, nutritional needs, and early detection of pregnancy-related complications. This shift is supported by the spread of mobile health applications and telemedicine, which make maternal health information more accessible even in rural or low-resource areas. The rising literacy rate among women in developing countries is also contributing to improved decision-making regarding maternal healthcare, ultimately boosting demand for specialized services and preventive care solutions.
• Rising Government and Institutional Support: International organizations, and private healthcare players to reduce maternal mortality rates and improve healthcare infrastructure. Initiatives like the United Nations Sustainable Development Goal 3.1, which targets a significant reduction in maternal mortality by 2030, have pushed countries to strengthen maternal healthcare services. Many governments are offering free or subsidized maternal health programs, upgrading medical facilities, and training skilled birth attendants. Additionally, global funding from agencies like WHO and UNICEF for maternal health projects is enabling better access to care, especially in underserved regions.

Market Challenges

• Inequality in Access to Healthcare: Despite progress, unequal access to quality maternal healthcare remains a significant challenge, particularly in low-income and rural areas. Women in these regions often face barriers such as poor transportation infrastructure, shortage of skilled medical staff, and lack of nearby healthcare facilities. Economic disparities also limit access to advanced treatments and diagnostics, while cultural factors and gender discrimination can prevent women from seeking timely care. This gap between urban and rural healthcare services creates a persistent challenge in achieving equitable maternal health outcomes worldwide.
• Shortage of Skilled Healthcare Professionals: A global shortage of qualified obstetricians, gynecologists, midwives, and nurses is another critical challenge. The World Health Organization has highlighted that many countries fall short of the recommended number of skilled birth attendants per population. This shortage leads to overburdened staff, reduced quality of care, and increased risks during pregnancy and childbirth. Additionally, in many regions, healthcare workers lack continuous professional training, which hinders their ability to handle high-risk pregnancies or emergencies effectively.

Market Trends

• Integration of Digital Health and Telemedicine: The maternal health industry is witnessing a rapid adoption of telehealth, mobile applications, and AI-powered diagnostic tools. These technologies enable remote monitoring of pregnant women, virtual consultations, and access to personalized health plans. Wearable devices are being used to track vital signs such as blood pressure, fetal heart rate, and glucose levels, providing timely alerts to healthcare providers. This digital transformation is especially beneficial for women in remote areas, helping bridge the gap in healthcare delivery.
• Focus on Holistic and Personalized Maternal Care: There is a growing trend towards personalized and holistic maternal care that goes beyond clinical services to include mental health support, nutritional counseling, and postnatal wellness programs. Healthcare providers are increasingly offering tailored plans based on individual health history, cultural preferences, and lifestyle factors. This shift is being driven by the recognition that maternal health is multidimensional, and optimal outcomes require comprehensive physical, emotional, and social support.

Intrauterine pregnancy dominates the global maternal health industry because it represents the natural and most common type of pregnancy, accounting for the vast majority of viable gestations that require standard maternal healthcare services.

Intrauterine pregnancy is the leading segment in the global maternal health industry primarily because it is the natural, physiologically intended location for fetal development, making it the most prevalent and clinically manageable type of pregnancy worldwide. Unlike ectopic or abnormal pregnancies, intrauterine pregnancies generally progress within the uterus, allowing for safe monitoring, standard prenatal interventions, and delivery under normal or controlled conditions. Statistically, the overwhelming majority of pregnancies are intrauterine, which directly translates to higher demand for routine maternal healthcare services such as antenatal checkups, ultrasound imaging, laboratory testing, nutritional supplementation, and obstetric consultations. This prevalence makes intrauterine pregnancy the central focus of public health policies, healthcare provider training, and clinical infrastructure. From a medical perspective, intrauterine pregnancies carry lower inherent risks compared to abnormal gestations, which means healthcare systems can concentrate on preventive and supportive measures to ensure maternal and fetal well-being. The growing global emphasis on reducing maternal and neonatal mortality has led to expanded access to antenatal care, skilled birth attendants, and safe delivery facilities services that primarily cater to intrauterine pregnancies. Furthermore, technological advancements in prenatal diagnostics, fetal monitoring, and obstetric care are almost entirely designed for intrauterine cases, reinforcing their market dominance. Rising awareness among women about the importance of early and regular prenatal visits has also contributed to the increased detection and care of intrauterine pregnancies, improving health outcomes and boosting associated healthcare demand.

Gestational Diabetes Mellitus (GDM) leads in the global maternal health complication segment due to its rapidly increasing prevalence worldwide, driven by rising obesity rates, sedentary lifestyles, and delayed maternal age.

Gestational Diabetes Mellitus (GDM) has emerged as the most common and significant pregnancy-related complication in the global maternal health industry, primarily due to its rising incidence across both developed and developing regions. The increasing prevalence is closely linked to modern lifestyle changes such as poor dietary patterns, reduced physical activity, and urban sedentary habits that contribute to higher rates of overweight and obesity among women of reproductive age. Additionally, the global trend of women delaying pregnancy into their 30s and 40s increases the risk of insulin resistance during gestation, making GDM more likely. Medical advancements and expanded screening programs have also contributed to higher reported cases, as earlier and more frequent glucose tolerance testing during pregnancy leads to greater detection rates. Unlike some other complications that occur in smaller subsets of pregnancies, GDM affects a substantial portion of expectant mothers estimates suggest it impacts between 7% and 20% of pregnancies globally, with higher rates in certain Asia-Pacific and Middle Eastern populations. This widespread occurrence makes it a major focus of maternal health strategies, as uncontrolled GDM can result in serious complications, including preeclampsia, macrosomia (large birth weight), preterm birth, and long-term health risks for both mother and child, such as Type 2 diabetes and metabolic syndrome. The economic burden of GDM is also significant, driving healthcare systems to prioritize its prevention, monitoring, and management. In many countries, GDM management protocols have become an integral part of antenatal care, involving regular blood glucose monitoring, nutritional counseling, lifestyle modification programs, and in some cases, insulin therapy. Pharmaceutical companies, diagnostic firms, and health technology providers have developed specialized products and services targeted at GDM, further fueling its prominence in the maternal health market.

Vaginal delivery leads in the global maternal health industry because it is the most natural, cost-effective, and commonly preferred childbirth method, accounting for the majority of births worldwide.

Vaginal delivery remains the dominant childbirth method in the global maternal health industry due to its natural physiological process, lower medical intervention requirements, and widespread acceptance across cultures and healthcare systems. Globally, the majority of births occur through vaginal delivery, primarily because it is the body’s natural mechanism for childbirth, often requiring fewer surgical resources and enabling faster maternal recovery compared to cesarean sections. In many parts of the world especially in low-and middle-income countries limited access to surgical facilities and trained surgeons makes vaginal delivery not only the preferred choice but also the most feasible one. From a medical perspective, vaginal births generally involve shorter hospital stays, reduced postpartum complications, and quicker return to normal activity, making them cost-effective for both families and healthcare systems. These advantages are reinforced by public health policies and WHO recommendations, which promote vaginal delivery as the safest option in uncomplicated pregnancies. Moreover, vaginal delivery is associated with certain long-term health benefits for both mother and child, including lower risks of respiratory issues in newborns and reduced likelihood of maternal surgical complications. Advancements in obstetric care such as better pain management techniques, skilled birth attendants, and improved prenatal screening have made vaginal deliveries safer, even in high-risk settings. Cultural and societal norms also play a significant role; in many regions, vaginal birth is seen as a rite of passage and is strongly preferred unless medical necessity dictates otherwise.

Hospitals lead in the global maternal health industry because they offer comprehensive, specialized, and emergency-ready care for pregnancy, childbirth, and related complications, making them the primary choice for safe deliveries worldwide.

Hospitals dominate the maternal health industry application segment primarily because they provide the most comprehensive range of services for pregnancy, childbirth, and postnatal care under one roof, ensuring safety for both mother and child. As maternal health involves multiple stages antenatal monitoring, labor and delivery, and postpartum recovery hospitals are uniquely equipped with specialized infrastructure, skilled obstetricians, gynecologists, anesthesiologists, neonatologists, and nursing staff to manage normal deliveries as well as high-risk and emergency situations. Unlike smaller clinics or home-based care, hospitals can immediately address life-threatening complications such as postpartum hemorrhage, preeclampsia, obstructed labor, or fetal distress through surgical intervention, advanced diagnostics, and intensive care facilities. This capability is particularly critical given the ongoing global emphasis on reducing maternal and neonatal mortality rates. In both developed and developing countries, government health policies and insurance coverage often encourage or mandate hospital-based deliveries to ensure access to skilled birth attendants and emergency obstetric care. Additionally, hospitals are preferred due to their integration of modern diagnostic technologies, fetal monitoring systems, and neonatal intensive care units (NICUs), which improve survival rates for premature or at-risk newborns. In urban areas, the growing trend of planned deliveries, including elective C-sections and pain-managed vaginal births, further increases hospital utilization. In rural and semi-urban settings, public hospitals serve as the central point of maternal healthcare, often supported by national maternal health programs, international aid, and NGO partnerships. Economic growth in emerging markets has also led to the expansion of private hospitals and maternity wards, offering higher comfort levels, personalized care, and advanced birthing options, attracting middle-and high-income families.

Pre-natal care leads in the global maternal health industry because it is essential for monitoring maternal and fetal health, preventing complications, and ensuring safe pregnancy outcomes, making it the most widely utilized maternal health service.

Pre-natal care dominates the maternal health industry because it serves as the cornerstone of a healthy pregnancy, focusing on early detection, prevention, and management of potential risks to both mother and child. It encompasses a comprehensive range of medical, nutritional, and educational services delivered throughout the gestation period, ensuring that complications such as gestational diabetes, preeclampsia, anemia, and fetal growth restrictions are identified and managed promptly. The World Health Organization and national health agencies strongly advocate for regular pre-natal visits as a global standard, with recommendations for multiple check-ups during pregnancy to track maternal vital signs, monitor fetal development, and provide necessary interventions. This strong policy support, combined with growing public awareness about the importance of maternal health, drives the widespread adoption of pre-natal services. Pre-natal care also plays a critical role in promoting maternal education, including guidance on nutrition, physical activity, safe medications, and preparation for childbirth, empowering women to make informed decisions. In both developed and developing regions, healthcare systems allocate significant resources to expanding pre-natal care access, especially in rural and underserved areas where maternal mortality rates have historically been higher. Technological advancements such as portable ultrasound devices, telemedicine consultations, and point-of-care diagnostic tools have made pre-natal services more accessible, even in remote communities. The private sector has also invested heavily in specialized maternity clinics and wellness programs offering personalized pre-natal packages, attracting middle-and high-income groups.

Normal pregnancy leads in the global maternal health industry because it represents the vast majority of all pregnancies, requiring routine maternal care without complex interventions, making it the primary focus of global maternal health services.

Normal pregnancy dominates the global maternal health industry because it accounts for the highest share of pregnancies worldwide, characterized by the absence of major medical complications and managed primarily through standard prenatal, delivery, and postnatal care. Unlike high-risk pregnancies, which require specialized monitoring and interventions, normal pregnancies typically progress without serious maternal or fetal health threats, allowing healthcare providers to follow established, cost-effective care protocols. This prevalence makes normal pregnancy the central focus of maternal health programs, public policies, and healthcare infrastructure planning. In most regions, the majority of expectant mothers fall into this category, ensuring a steady demand for routine antenatal check-ups, nutritional guidance, basic laboratory testing, and ultrasound monitoring. Governments and international health organizations, including the WHO, have built extensive maternal health frameworks around supporting normal pregnancies, emphasizing accessibility to skilled birth attendants, safe delivery environments, and basic postnatal follow-up. The rise in institutional deliveries, even for low-risk cases, has further increased the role of hospitals, maternity clinics, and trained midwives in managing normal pregnancies. Cultural norms and family preferences also strongly favor routine maternal care for normal pregnancies, as they are seen as natural life events that benefit from professional oversight to ensure safety. Technological advancements such as portable ultrasound machines, telehealth consultations, and improved screening tools have made it easier to monitor normal pregnancies in both urban and rural areas, expanding access to care.

Asia-Pacific leads the global maternal health industry due to its large and growing population of women of childbearing age, combined with increasing healthcare investments and government initiatives to improve maternal care access and quality.

Asia-Pacific’s dominance in the global maternal health industry is primarily driven by its massive demographic base, which includes the highest number of women in their reproductive years compared to any other region. Countries such as India, China, Indonesia, and the Philippines have large populations with high birth rates, naturally increasing the demand for maternal healthcare services, products, and interventions. This demographic strength is further amplified by rapid economic growth, which has enabled governments and private players to expand healthcare infrastructure, introduce advanced medical technologies, and improve service delivery in both urban and rural areas. In recent years, regional governments have prioritized maternal health as part of broader public health agendas, introducing initiatives to reduce maternal mortality rates, expand antenatal and postnatal care coverage, and improve access to skilled birth attendants. For instance, India’s Janani Suraksha Yojana and China’s maternal health insurance schemes have significantly enhanced access to care for millions of women. Alongside public programs, there has been a surge in private healthcare providers, NGOs, and international organizations investing in maternal health initiatives, bringing innovation in telemedicine, portable diagnostic devices, and community outreach. Moreover, rising awareness among women about the importance of prenatal nutrition, safe childbirth practices, and postpartum recovery has spurred demand for related products such as supplements, diagnostic tests, and maternity-focused health services.

• In January 2025, GE HealthCare introduced its enhanced Voluson Expert Series (models 22, 20, 18), which received FDA-clearance, featuring AI-powered imaging, advanced automation (like SonoLyst and Graphicflow), and ergonomic design to boost early detection and exam efficiency in women’s health ultrasound.
• In March 2025, in the midst of growing uncertainty over international research funding, a new global health research program was just established that uses music to help pregnant women's mental health. CHIME is a significant investment in maternal mental health research in the Global South, having been funded with over £2.8 million (around US$3.5 million) by the UK's National Institute for Health and Care Research (NIHR).
• In January 2025, HRSA commemorated a historic year of strengthening maternal health programs by announcing increased funding, policy action, and reports. $9 million in additional funds to maintain and expand the state of the Enhancing Maternal Health Initiative.
• In October 2024, 15 states will receive awards totaling about $19 million from the U.S. Department of Health and Human Services (HHS)'s Health Resources and Services Administration (HRSA) to develop and put into practice creative solutions to the maternal health issue.
• In April 2024, LunaJoy Health announced the introduction of LunaCare, a revolutionary integrated care program designed to enhance mother mental health outcomes and reduce inequities in maternal health care. strengthened by fresh investment of $4.2 million.
• In March 2024, Arrowhead Regional Medical Center (ARMC) was listed as a “Birthing-Friendly” hospital for its commitment to providing evidence-based, high-quality maternity care to women and their families in the Inland Empire.
• In February 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the US Food & Drug Administration has accepted zuranolone's New Drug Application for treating PPD and major depressive disorder. The claim has been granted priority review, and the FDA has assigned an August 5, 2023, Prescription Drug User Fee Act action date.

This product will be delivered within 2 business days.